The E5 proteins

Virology

Volumn 445, Issue 1-2, 2013, Pages 99-114

  DiMaio, Daniel ^a,b,c   Petti, Lisa M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

Cervical cancer; EGF receptor; HPV; Papillomaviruses; PDGF receptor; Transmembrane proteins; Vacuolar ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS PROTEIN; VIRUS PROTEIN E5;

ANTIGEN EXPRESSION; ARTICLE; BIOLOGICAL ACTIVITY; BOVINE PAPILLOMAVIRUS TYPE 1; BOVINE PAPILLOMAVIRUS TYPE 4; CARCINOGENESIS; CARCINOGENICITY; CELL COMMUNICATION; CELL IMMORTALIZATION; CELL TRANSFORMATION; CELL VACUOLE; ENZYME ACTIVATION; FIBROPAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOREGULATION; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SUBUNIT; PROTEIN TARGETING; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

CERVICAL CANCER; EGF RECEPTOR; HPV; PAPILLOMAVIRUSES; PDGF RECEPTOR; TRANSMEMBRANE PROTEINS; VACUOLAR ATPASE;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DELTAPAPILLOMAVIRUS; HOST-PATHOGEN INTERACTIONS; IMMUNE EVASION; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; VIRUS REPLICATION;

ANIMALIA; HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84884355894     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.05.006     Document Type: Article

References (180)

1. +-ATPase is not sufficient for biological activity, using mammalian and yeast expression systems. Virology 2000, 272:315-325.
2. Adduci A.J., Schlegel R. The transmembrane domain of the E5 oncoprotein contains functionally discrete helical faces. J. Biol. Chem. 1999, 274:10249-10258.
3. Anderson R.A., Scobie L., O'Neil B.W., Grindlay G.J., Campo MS, Viral proteins of bovine papillomavirus type 4 during the development of alimentary canal tumours. Vet J. 1997, 154(1):69-78.
4. +-ATPase mutants transform cells and define a binding site for the papillomavirus E5 oncoprotein. J. Biol. Chem. 1995, 270:6830-6837.
5. +-ATPase. J. Gen. Virol. 2001, 82:2353-2362.
6. Ashrafi G.H., Brown D.R., Fife K.H., Campo M.S. Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res. 2006, 120(1-2):208-211.
7. Ashrafi G.H., Haghshenas M., Marchetti B., Campo M.S. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int. J. Cancer 2006, 119:2105-2112.
8. Ashrafi G.H., Haghshenas M.R., Marchetti B., O'Brien P.M., Campo M.S. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int. J. Cancer 2005, 113:276-283.
9. Ashrafi G.H., Pitts J.D., Faccini A., McLean P., O'Brien P.M., Finbow M.E., Campo M.S. Binding of bovine papillomavirus type 4 E8 to ductin (16K proteolipid), down-regulation of gap junction intercellular communication and full cell transformation are independent events. J. Gen. Virol. 2000, 81:689-694.
10. Ashrafi G.H., Tsirimonaki E., Marchetti B., O'Brien P.M., Sibbet G.J., Andrew L., Campo M.S. Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 2002, 21:248-259.
11. Auvinen E., Alonso A., Auvinen P. Human papillomavirus type 16 E5 protein colocalizes with the antiapoptotic Bcl-2 protein. Arch. Virol. 2004, 149:1745-1759.
12. Barbaresi S., Cortese M.S., Quinn J., Ashrafi G.H., Graham S.V., Campo M.S. Effects of human papillomavirus type 16 E5 deletion mutants on epithelial morphology: functional characterization of each transmembrane domain. J. Gen. Virol. 2010, 91(PART 2):521-530.
13. Belleudi F., Leone L., Purpura V., Cannella F., Scrofani C., Torrisi M.R. HPV16 E5 affects the KGFR/FGFR2b-mediated epithelial growth through alteration of the receptor expression, signaling and endocytic traffic. Oncogene 2011, 30(50):4963-4976.
14. Bergman P., Ustav M., Sedman J., Moreno-Lopez J., Vennstrom B., Pettersson U. The E5 gene of bovine papillomavirus type 1 is sufficient for complete oncogenic transformation of mouse fibroblasts. Oncogene 1988, 2:453-459.
15. Bocaneti F., Altamura G., Corteggio A., Martano M., Roperto F., Velescu E., Borzacchiello G. Expression of platelet derived growth factor beta receptor, its activation and downstream signals in bovine cutaneous fibropapillomas. Res. Vet. Sci. 94, 596-601 2012.
16. Borzacchiello G., Mogavero S., De Vita G., Roperto S., Della Salda L., Roperto F. Activated platelet-derived growth factor beta receptor expression, PI3K-AKT pathway molecular analysis, and transforming signals in equine sarcoids. Vet. Pathol. 2009, 46(4):589-597.
17. Borzacchiello G., Russo V., Gentile F., roperto F., Venuti A., Nitsch L., Campo M.S., Roperto S. Bovine papillomavirus E5 oncoprotein binds to the activated form of the platelet-derived growth factor beta receptor in naturally occurring bovine urinary blader tumours. Oncogene 2006, 25:1251-1260.
18. Bouvard V., Matlashewski G., Gu Z.-M., Storey A., Banks L. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 1994, 203:73-80.
19. Brandt S., Haralambus R., Schoster A., Kirnbauer R., Stanek C. Peripheral blood mononuclear cells represent a reservoir of bovine papillomavirus DNA in sarcoid-affected equines. J. Gen. Virol. 2008, 89(Pt 6):1390-1395.
20. Bravo I.G., Alonso A. Mucosal human papillomaviruses encode four different E5 proteins whose chemistry and phylogeny correlate with malignant or benign growth. J. Virol. 2004, 78:13613-13626.
21. Bravo I.G., Crusius K., Alonso A. The E5 protein of the human papillomavirus type 16 modulates composition and dynamics of membrane lipids in keratinocytes. Arch. Virol. 2005, 150:231-246.
22. +-ATPase function and stability in Saccharomyces cerevisiae. Virology 2001, 280:169-175.
23. Bubb V., McCance D.J., Schlegel R. DNA sequence of the HPV-16 E5 ORF and the structural conservation of its encoded protein. Virology 1988, 163(1):243-246.
24. Burkhardt A., DiMaio D., Schlegel R. Genetic and biochemical definition of the bovine papillomavirus E5 transforming protein. EMBO J. 1987, 6(8):2381-2385.
25. Burkhardt A., Willingham M., Gay C., Jeang K.-T., Schlegel R. The E5 oncoprotein of bovine papillomavirus is oriented asymmetrically in Golgi and plasma membranes. Virology 1989, 170:334-339.
26. Burnett S., Jareborg N., DiMaio D. Localization of bovine papillomavirus type 1 E5 protein to transformed basal keratinocytes and permissive differentiated cells in fibropapilloma tissue. Proc. Natl. Acad. Sci. USA 1992, 89(12):5665-5669.
27. Cammett T.J., Jun S.J., Cohen E.B., Barrera F.N., Engelman D.M., DiMaio D. Construction and genetic selection of small transmembrane proteins that activate the human erythropoietin receptor. Proc. Natl. Acad. Sci USA 2010, 107:3447-3452.
28. Campo M.S., Graham S.V., Cortese M.S., Ashrafi G.H., Araibi E.H., Dornan E.S., Miners K., Nunes C., Man S. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 2010, 407(1):137-142.
29. Carr E.A., Theon A.P., Madewell B.R., Hitchcock M.E., Schlegel R., Schiller J.T. Expression of a transforming gene (E5) of bovine papillomavirus in sarcoids obtained from horses. Am. J. Vet. Res. 2001, 62(8):1212-1217.
30. Chang J.L., Tsao Y.P., Liu D.W., Huang S.J., Lee W.H., Chen S.L. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J. Biomed. Sci. 2001, 8(2):206-213.
31. Chen S.-L., Tsai T.-C., Han C.-P., Tsao Y.-P. Mutational analysis of human papillomavirus type 11 E5a oncoprotein. J. Virol. 1996, 70:3502-3508.
32. Chen S.L., Huang C.H., Tsai T.C., Lu K.Y., Tsao Y.P. The regulation mechanism of c-jun and junB by human papillomavirus type 16 E5 oncoprotein. Arch. Virol. 1996, 141:791-800.
33. Chen S.L., Lin S.T., Tsai T.C., Hsiao W.C., Tsao Y.P. ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein. Oncogene 2007, 26(1):42-53.
34. Chen S.L., Lin Y.K., Li L.Y., Tsao Y.P., Lo H.Y., Wang W.B., Tsai T.C. E5 proteins of human papillomavirus types 11 and 16 transactivate the c-fos promoter through the NF1 binding element. J. Virol. 1996, 70(12):8558-8563.
35. Chen S.L., Mounts P. Transforming activity of E5a protein of human papillomavirus type 6 in NIH 3T3 and C127 cells. J. Virol 1990, 64:3226-3233.
36. Choo K.B., Pan C.C., Liu M.S., Ng H.T., Chen C.P., Lee Y.N., Chao C.F., Meng C.L., Yeh M.Y., Han S.H. Presence of episomal and integrated human papillomavirus DNA sequences in cervical carcinoma. J. Med. Virol. 1987, 21(2):101-107.
37. Cohen B.D., Goldstein D.J., Rutledge L., Vass W.C., Lowy D.R., Schlegel R., Schiller J.T. Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain. J. Virol. 1993, 67:5303-5311.
38. Conrad M., Bubb V.J., Schlegel R. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J. Virol. 1993, 67:6170-6178.
39. Conrad M., Goldstein D., Andresson T., Schlegel R. The E5 protein of HPV-6, but not HPV-16, associates efficiently with cellular growth factor receptors. Virology 1994, 200:796-800.
40. Corteggio A., Altamura G., Roperto F., Borzacchiello G. Bovine papillomavirus E5 and E7 oncoproteins in naturally occurring tumors: are two better than one?. Infect. Agent Cancer 2013, 8(1):1.
41. Corteggio A., Di Geronimo O., Roperto S., Roperto F., Borzacchiello G. Activated platelet-derived growth factor beta receptor and Ras-mitogen-activated protein kinase pathway in natural bovine urinary bladder carcinomas. Vet. J. 2011, 191(3):393-395.
42. Corteggio A., Urraro C., Roperto S., Roperto F., Borzacchiello G. Phosphatidylinositol-3-kinase-AKT pathway, phospho-JUN and phospho-JNK expression in spontaneously arising bovine urinary bladder tumours. J. Comp. Pathol. 2010, 143(2-3):173-178.
43. Cortese M.S., Ashrafi G.H., Campo M.S. All 4 di-leucine motifs in the first hydrophobic domain of the E5 oncoprotein of human papillomavirus type 16 are essential for surface MHC class I downregulation activity and E5 endomembrane localization. Int. J. Cancer 2010, 126:1675-1682.
44. Cromme F.V., Meijer C.J., Snijders P.J., Uyterlinde A., Kenemans P., Helmerhorst T., Stern P.L., van den Brule A.J., Walboomers J.M. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br. J. Cancer. 1993, 67(6):1372-1380.
45. Crusius K., Auvinen E., Alonso A. Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 1997, 15:1437-1444.
46. Crusius K., Auvinen E., Steuer B., Gaissert H., Alonso A. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp. Cell Res. 1998, 241:76-83.
47. Crusius K., Kaszkin M., Kinzel V., Alonso A. The human papillomavirus type 16 E5 protein modulates phospholipase C-g-1 activity and phosphatidyl inositol turnover in mouse fibroblasts. Oncogene 1999, 18:6714-6718.
48. Crusius K., Rodriguez I., Alonso A. The human papillomavirus type 16 E5 protein modulates ERK1/2 and p38 MAP kinase activation by an EGFR-independent process in stressed human keratinocytes. Virus Genes 2000, 20:65-69.
49. Cullen A.P., Reid R., Campion M., Lorincz A.T. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol. 1991, 65(2):606-612.
50. Di Domenico F., Foppoli C., Blarzino C., Perluigi M., Paolini F., Morici S., Coccia R., Cini C., De Marco F. Expression of human papilloma virus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity. J. Exp. Clin. Cancer Res. 2009, 28:4.
51. DiMaio D., Guralski D., Schiller J.T. Translation of open reading frame E5 of bovine papillomavirus is required for its transforming activity. Proc. Natl. Acad. Sci. USA 1986, 83(6):1797-1801.
52. Disbrow G.L., Hanover J.A., Schlegel R. Endoplasmic reticulum-localized human papillomavirus type 16 E5 protein alters endosomal pH but not trans-Golgi pH. J. Virol. 2005, 79:5839-5846.
53. Disbrow G.L., Sunitha I., Baker C.C., Hanover J., Schlegel R. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 2003, 311:105-114.
54. Drummond-Barbosa D.A., Vaillancourt R.R., Kazlauskas A., DiMaio D. Ligand-independent activation of the platelet-derived growth factor beta receptor: requirements for bovine papillomavirus E5-induced mitogenic signaling. Mol. Cell. Biol. 1995, 15(5):2570-2581.
55. Faccini A.M., Cairney M., Ashrafi G.H., Finbow M.E., Campo M.S., Pitts J.D. The bovine papillomavirus type 4 E8 protein binds to ductin and causes loss of gap junctional intercellular communication in primary fibroblasts. J. Virol. 1996, 70:9041-9045.
56. Fehrmann F., Klumpp D.J., Laimins L.A. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J. Virol. 2003, 77:2819-2831.
57. Freeman-Cook L., Dixon A.M., Frank J.B., Xia Y., Ely L., Gerstein M., Engelman D.M., DiMaio D. Selection and characterization of small random transmembrane proteins that bind and activate the platelet-derived growth factor β receptor. J. Mol. Biol. 2004, 338:907-920.
58. Freeman-Cook L.L., Edwards A.P.B., Dixon A.M., Yates K.E., Ely L., Engelman D.M., DiMaio D. Specific locations of hydrophilic amino acids in constructed transmembrane ligands of the platelet-derived growth factor β receptor. J. Mol. Biol. 2005, 345(907-921).
59. Gao P., Zheng J. High-risk HPV E5-induced cell fusion: a critical initiating event in the early stage of HPV-associated cervical cancer. Virol. J. 2010, 7:238.
60. Genther-Williams S.M., Disbrow G.L., Schlegel R., Lee D., Threadgill D.W., Lambert P.F. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res. 2005, 65:6534-6542.
61. Genther S.M., Sterling S., Duensing S., Munger K., Sattler C., Lambert P.F. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J. Virol. 2003, 77:2832-2842.
62. Gieswein C.E., Sharom F.J., Wildeman A.G. Oligomerization of the E5 protein of human papillomavirus type 16 occurs through multiple hydrophobic regions. Virology 2003, 313:415-426.
63. Goldstein D.J., Andresson T., Sparkowski J.J., Schlegel R. The BPV-1 E5 protein, the 16 kDa membrane pore-forming protein and the PDGF receptor exist in a complex that is dependent on hydrophobic transmembrane interactions. EMBO J. 1992, 11:4851-4859.
64. Goldstein D.J., Finbow M.E., Andresson T., McLean P., Smith K., Bubb V., Schlegel R. Bovine papillomavirus E5 oncoprotein binds to the 16K component of vacuolar H(+)-ATPases. Nature 1991, 352:347-349.
65. Goldstein D.J., Li W., Wang L.-M., Heidaran M.A., Aaronson S.A., Shinn R., Schlegel R., Pierce J.H. The bovine papillomavirus type 1 E5 transforming protein specifically binds and activates the beta-type receptor for platelet-derived growth factor but not other tyrosine kinase-containing receptors to induce cellular transformation. J. Virol. 1994, 68:4432-4441.
66. Grindlay G.J., Campo M.S., O'Brien V. Transactivation of the cyclin A promoter by bovine papillomavirus type 4 E5 protein. Virus Res. 2005, 108:29-38.
67. Gruener M., Bravo I.G., Momburg F., Alonso A., Tomakidi P. The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells. Virol. J. 2007, 4:116.
68. Gu Z.-M., Matlashewski G. Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. J. Virol. 1995, 69:8051-8056.
69. Halbert C.L., Galloway D.A. Identification of the E5 open reading frame of human papillomavirus type 16. J. Virol. 1988, 62(3):1071-1075.
70. Horwitz B.H., Burkhardt A.L., Schlegel R., DiMaio D. 44-amino-acid E5 transforming protein of bovine papillomavirus requires a hydrophobic core and specific carboxyl-terminal amino acids. Mol. Cell. Biol. 1988, 8(10):4071-4078.
71. Horwitz B.H., Weinstat D.L., DiMaio D. Transforming activity of a 16-amino-acid segment of the bovine papillomavirus E5 protein linked to random sequences of hydrophobic amino acids. J. Virol. 1989, 63(11):4515-4519.
72. Hu L., Ceresa B.P. Characterization of the plasma membrane localization and orientation of HPV16 E5 for cell-cell fusion. Virology 2009, 393(1):135-143.
73. Hu L., Plafker K., Vorozhko V., Zuna R.E., Hanigan M.H., Gorbsky G.J., Plafker S.M., Angeletti P.C., Ceresa B.P. Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion. Virology 2009, 384(1):125-134.
74. Hu L., Potapova T.A., Li S., Rankin S., Gorbsky G.J., Angeletti P.C., Ceresa B.P. Expression of HPV16 E5 produces enlarged nuclei and polyploidy through endoreplication. Virology 2010, 405(2):342-351.
75. Hwang E.S., Nottoli T., DiMaio D. The HPV16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology 1995, 211(1):227-233.
76. Kabsch K., Alonso A. The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms. J. Virol. 2002, 76:12162-12172.
77. Kabsch K., Mossadegh N., Kohl A., Komposch G., Schenkel J., Alonso A., Tomakidi P. The HPV-16 E5 protein inhibits TRAIL- and FasL-mediated apoptosis in human keratinocyte raft cultures. Intervirology 2004, 47:48-56.
78. Kell B., Jewers R.J., Cason J., Pakarian F., Kaye J.N., Best J.M. Detection of E5 oncoprotein in human papillomavirus type 16-positive cervical scrapes using antibodies raised to synthetic peptides. J. Gen. Virol. 1994, 75(PART 9):2451-2456.
79. Kilk A., Talpsepp T., Vali U., Ustav M. Bovine papillomavirus oncoprotein E5 induces the NF kappa B activation through superoxide radicals. Biochem. Mol. Biol. Int. 1996, 40(4):689-697.
80. Kim S.H., Juhnn Y.S., Kang S., Park S.W., Sung M.W., Bang Y.J., Song Y.S. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ ERK1,2 and PI3K/Akt. Cell. Mol. Life Sci. 2006, 63(7-8):930-938.
81. Kim S.H., Oh J.M., No J.H., Bang Y.J., Juhnn Y.S., Song Y.S. Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 2009, 30(5):753-757.
82. King G., Oates J., Patel D., van den Berg H.A., Dixon A.M. Towards a structural understanding of the smallest known oncoprotein: investigation of the bovine papillomavirus E5 protein using solution-state NMR. Biochim. Biophys. Acta 2011, 1808(6):1493-1501.
83. Kivi N., Greco D., Auvinen P., Auvinen E. Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene 2008, 27(18):2532-2541.
84. Klein O., Kegler-Ebo D., Su J., Smith S., DiMaio D. The bovine papillomavirus E5 protein requires a juxtamembrane negative charge for activation of the platelet-derived growth factor beta receptor and transformation of C127 cells. J. Virol. 1999, 73(4):3264-3272.
85. Klein O., Polack G.W., Surti T., Kegler-Ebo D., Smith S.O., DiMaio D. Role of glutamine 17 of the bovine papillomavirus E5 protein in platelet-derived growth factor beta receptor activation and cell transformation. J. Virol. 1998, 72(11):8921-8932.
86. Krawczyk E., Hanover J.A., Schlegel R., Suprynowicz F.A. Karyopherin beta3: a new cellular target for the HPV-16 E5 oncoprotein. Biochem. Biophys. Res. Commun. 2008, 371(4):684-688.
87. Krawczyk E., Suprynowicz F.A., Hebert J.D., Kamonjoh C.M., Schlegel R. The human papillomavirus type 16 E5 oncoprotein translocates calpactin I to the perinuclear region. J. Virol. 2011, 85(21):10968-10975.
88. Krawczyk E., Suprynowicz F.A., Liu X., Dai Y., Hartmann D.P., Hanover J., Schlegel R. Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins. Am. J. Pathol. 2008, 173(3):682-688.
89. Krawczyk E., Suprynowicz F.A., Sudarshan S.R., Schlegel R. Membrane orientation of the human papillomavirus type 16 E5 oncoprotein. J. Virol. 2010, 84(4):1696-1703.
90. Kulke R., Horwitz B.H., Zibello T., DiMaio D. The central hydrophobic domain of the bovine papillomavirus E5 transforming protein can be functionally replaced by many hydrophobic amino acid sequences containing a glutamine. J. Virol. 1992, 66(1):505-511.
91. Lai C.-C., Edwards A.P.B., DiMaio D. Productive interaction between transmembrane mutants of the bovine papillomavirus E5 protein and the platelet-derived growth factor β receptor. J. Virol. 2005, 79:1924-1929.
92. Lai C.C., Henningson C., DiMaio D. Bovine papillomavirus E5 protein induces oligomerization and trans-phosphorylation of the platelet-derived growth factor β receptor. Proc. Natl. Acad. Sci. USA 1998, 95:15241-15246.
93. Lai C.C., Henningson C., DiMaio D. Bovine papillomavirus E5 protein induces the formation of signal transduction complexes containing dimeric activated platelet-derived growth factor β receptor and associated signaling proteins. J. Biol. Chem 2000, 275:9832-9840.
94. Lazarczyk M., Pons C., Mendoza J.A., Cassonnet P., Jacob Y., Favre M. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J. Exp. Med. 2008, 205(1):35-42.
95. Leechanachai P., Banks L., Moreau F., Matlashewski G. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 1992, 7:19-25.
96. Leptak C., Ramon y Cajal S., Kulke R., Horwitz B.H., Riese D.J., Dotto G.P., DiMaio D. Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. J. Virol. 1991, 65(12):7078-7083.
97. Lewis C., Baro M.F., Marques M., Gruner M., Alonso A., Bravo I.G. The first hydrophobic region of the HPV16 E5 protein determines protein cellular location and facilitates anchorage-independent growth. Virol. J. 2008, 5:30.
98. Longworth M.S., Laimins L.A. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 2004, 68(2):362-372.
99. Marchetti B., Ashrafi G.H., Tsirimonaki E., O'Brien P.M., Campo M.S. The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surface. Oncogene 2002, 21:7808-7816.
100. Matsukura T., Koi S., Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 1989, 172(1):63-72.
101. Mattoon D., Gupta K., Doyon J., Loll P.J., DiMaio D. Identification of the transmembrane dimer interface of the bovine papillomavirus E5 protein. Oncogene 2001, 20:3824-3834.
102. Maufort J.P., Shai A., Pitot H.C., Lambert P.F. A role for HPV16 E5 in cervical carcinogenesis. Cancer Res. 2010, 70(7):2924-2931.
103. Maufort J.P., Williams S.M., Pitot H.C., Lambert P.F. Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res. 2007, 67(13):6106-6112.
104. McBride A.A., Dlugosz A., Baker C.C. Production of infectious bovine papillomavirus from cloned viral DNA by using an organotypic raft/xenograft technique. Proc. Natl. Acad. Sci. USA 2000, 97(10):5534-5539.
105. Meyer A.N., Xu Y.-F., Webster M.K., Smith A.S., Donoghue D.J. Cellular transformation by a transmembrane peptide: structural requirements for the bovine papillomavirus E5 oncoprotein. Proc. Natl. Acad. Sci. USA 1994, 91:4634-4638.
106. Miura S., Kawana K., Schust D.J., Fujii T., Yokoyama T., Iwasawa Y., Nagamatsu T., Adachi K., Tomio A., Tomio K., Kojima S., Yasugi T., Kozuma S., Taketani Y. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J. Virol. 2010, 84(22):11614-11623.
107. Nappi V.M., Petti L.M. Multiple transmembrane amino acid requirements suggest a highly specific interaction between the bovine papillomavirus E5 oncoprotein and the platelet-derived growth factor beta receptor. J. Virol. 2002, 76:7976-7986.
108. Nappi V.M., Schaefer J.A., Petti L.M. Molecular examination of the transmembrane requirements of the platelet-derived growth factor beta receptor for a productive interaction with the bovine papillomavirus E5 oncoprotein. J. Biol. Chem. 2002, 277:47149-47159.
109. Nath R., Mant C.A., Kell B., Cason J., Bible J.M. Analyses of variant human papillomavirus type-16 E5 proteins for their ability to induce mitogenesis of murine fibroblasts. Cancer. Cell. Int. 2006, 6:19.
110. Neary K., DiMaio D. Open reading frames E6 and E7 of bovine papillomavirus type 1 are both required for full transformation of mouse C127 cells. J. Virol. 1989, 63(1):259-266.
111. Nilson L.A., DiMaio D. Platelet-derived growth factor receptor can mediate tumorigenic transformation by the bovine papillomavirus E5 protein. Mol. Cell. Biol. 1993, 13(7):4137-4145.
112. Nilson L.A., Gottlieb R.L., Polack G.W., DiMaio D. Mutational analysis of the interaction between the bovine papillomavirus E5 transforming protein and the endogenous beta receptor for platelet-derived growth factor in mouse C127 cells. J. Virol. 1995, 69(9):5869-5874.
113. Nishio M., Tajima O., Furukawa K., Urano T. Over-expression of GM1 enhances cell proliferation with epidermal growth factor without affecting the receptor localization in the microdomain in PC12 cells. Int. J. Oncol. 2005, 26(1):191-199.
114. O'Brien P.M., Ashrafi G.H., Grindlay G.J., Anderson R., Campo M.S. A mutational analysis of the transforming functions of the E8 protein of bovine papillomavirus type 4. Virology 1999, 255:385-394.
115. O'Brien P.M., Grindlay G.J., Campo M.S. Cell transformation by the E5/E8 protein of bovine papillomavirus type 4. J. Biol. Chem. 2001, 276:33861-33868.
116. KIP1. Oncogene 1998, 17:293-301.
117. Oates J., Hicks M., Dafforn T.R., DiMaio D., Dixon A.M. In vitro dimerization of the bovine papillomavirus E5 protein transmembrane domain. Biochemistry 2008, 47:8985-8992.
118. Oelze I., Kartenbeck J., Crusius K., Alonso A. Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line. J. Virol. 1995, 69:4489-4494.
119. Oetke C., Auvinen E., Pawlita M., Alonso A. Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation. Arch. Virol. 2000, 145(10):2183-2191.
120. Oh J.M., Kim S.H., Cho E.A., Song Y.S., Kim W.H., Juhnn Y.S. Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. Carcinogenesis 2010, 31(3):402-410.
121. Oh J.M., Kim S.H., Lee Y.I., Seo M., Kim S.Y., Song Y.S., Kim W.H., Juhnn Y.S. Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis 2009, 30(1):141-149.
122. Pedroza-Saavedra A., Lam E.W., Esquivel-Guadarrama F., Gutierrez-Xicotencatl L. The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the down-regulation of p27(Kip1). Virology 2010, 400(1):44-52.
123. Petti L., DiMaio D. Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells. Proc. Natl. Acad. Sci. USA 1992, 89(15):6736-6740.
124. Petti L., DiMaio D. Specific interaction between the bovine papillomavirus E5 transforming protein and the beta receptor for platelet-derived growth factor in stably transformed and acutely transfected cells. J. Virol. 1994, 68(6):3582-3592.
125. Petti L., Nilson L.A., DiMaio D. Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J. 1991, 10(4):845-855.
126. Petti L.M., Ray F.A. Transformation of mortal human fibroblasts and activation of a growth inhibitory pathway by the bovine papillomavirus E5 oncoprotein. Cell. Growth Differ. 2000, 11:395-408.
127. Petti L.M., Reddy V., Smith S.O., DiMaio D. Identification of amino acids in the transmembrane and juxtamembrane domains of the platelet-derived growth factor receptor required for productive interaction with the bovine papillomavirus E5 protein. J. Virol. 1997, 71(10):7318-7327.
128. Petti L.M., Ricciardi E.C., Page H.J., Porter K.A. Transforming signals resulting from sustained activation of the PDGF β receptor in mortal human fibroblasts. J. Cell Sci. 2008, 121:1172-1182.
129. Pim D., Collins M., Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992, 7:27-32.
130. Ptacek J.B., Edwards A.P.B., Freeman-Cook L.L., DiMaio D. Packing contacts can mediate highly specific interactions between artificial transmembrane proteins and the PDGF b receptor. Proc. Natl. Acad. Sci. USA 2007, 104(11945-11950).
131. Regan J.A., Laimins L.A. Bap31 is a novel target of the human papillomavirus E5 protein. J. Virol. 2008, 82(20):10042-10051.
132. Riese D.J., DiMaio D. An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein. Oncogene 1995, 10(7):1431-1439.
133. Ritz U., Momburg F., Pilch H., Huber C., Maeurer M.J., Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int. J. Oncol. 2001, 19(6):1211-1220.
134. +-ATPase can be dissociated from the E5-mediated epidermal growth fator receptor overactivation. Oncogene 2000, 19:3727-3732.
135. Roperto S., Borzacchiello G., Esposito I., Riccardi M., Urraro C., Luca R., Corteggio A., Tate R., Cermola M., Paciello O., Roperto F. Productive infection of bovine papillomavirus type 2 in the placenta of pregnant cows affected with urinary bladder tumors. PLoS One 2012, 7(3):e33569.
136. Roperto S., Comazzi S., Ciusani E., Paolini F., Borzacchiello G., Esposito I., Luca R., Russo V., Urraro C., Venuti A., Roperto F. PBMCs are additional sites of productive infection of bovine papillomavirus type 2. J. Gen. Virol. 2011, 92(Pt 8):1787-1794.
137. Roperto S., De Tullio R., Raso C., Stifanese R., Russo V., Gaspari M., Borzacchiello G., Averna M., Paciello O., Cuda G., Roperto F. Calpain3 is expressed in a proteolitically active form in papillomavirus-associated urothelial tumors of the urinary bladder in cattle. PLoS One 2010, 5(4):e10299.
138. Roperto S., Russo V., Ozkul A., Sepici-Dincel A., Maiolino P., Borzacchiello G., Marcus I., Esposito I., Riccardi M.G., Roperto F. Bovine papillomavirus type 2 infects the urinary bladder of water buffalo (Bubalus bubalis) and plays a crucial role in bubaline urothelial carcinogenesis. J. Gen. Virol. 2013, 94(PART 2):403-408.
139. Sahab Z., Sudarshan S.R., Liu X., Zhang Y., Kirilyuk A., Kamonjoh C.M., Simic V., Dai Y., Byers S.W., Doorbar J., Suprynowicz F.A., Schlegel R. Quantitative measurement of human papillomavirus type 16 E5 oncoprotein levels in epithelial cell lines by mass spectrometry. J. Virol. 2012, 86(17):9465-9473.
140. Schapiro F., Sparkowski J., Adduci A., Suprynowicz F.A., Schlegel R., Grinstein S. Golgi alkalinization by the papillomavirus E5 oncoprotein. J. Cell. Biol. 2000, 148:305-315.
141. Scheideman E.H., Marlatt S.A., Xie Y., Hu Y., Sutton R.E., DiMaio D. Transmembrane protein aptamers that inhibit CCR5 expression and HIV coreceptor function. J. Virol. 2012, 86(19):10281-10292.
142. Schiffman M., Herrero R., Desalle R., Hildesheim A., Wacholder S., Rodriguez A.C., Bratti M.C., Sherman M.E., Morales J., Guillen D., Alfaro M., Hutchinson M., Wright T.C., Solomon D., Chen Z., Schussler J., Castle P.E., Burk R.D. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337:76-84.
143. Schiller J.T., Vass W.C., Vousden K.H., Lowy D.R. E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J. Virol. 1986, 57:1-6.
144. Schlegel R., Wade-Glass M., Rabson M.S., Yang Y.-C. The E5 transforming gene of bovine papillomavirus encodes a small hydrophobic protein. Science 1986, 233:464-467.
145. Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985, 314(6006):111-114.
146. Silva M.A., Silva K.M., Jesus A.L., Barros L.O., Corteggio A., Altamura G., Borzacchiello G., Freitas A.C. The presence and gene expression of bovine papillomavirus in the peripheral blood and semen of healthy horses. Transbound. Emerg. Dis. 2012, 10.1111/tbed.12036.
147. Silvestre O., Borzacchiello G., Nava D., Iovane G., Russo V., Vecchio D., D'Ausilio F., Gault E.A., Campo M.S., Paciello O. Bovine papillomavirus type 1 DNA and E5 oncoprotein expression in water buffalo fibropapillomas. Vet. Pathol. 2009, 46(4):636-641.
148. Sparkowski J., Anders J., Schlegel R. Mutation of the bovine papillomavirus E5 oncoprotein at amino acid 17 generates both high- and low-transforming variants. J. Virol. 1994, 68:6120-6123.
149. Sparkowski J., Mense M., Anders M., Schlegel R. E5 oncoprotein transmembrane mutants dissociate fibroblast transforming activity from 16-kilodalton protein binding and platelet-derived growth factor receptor binding and phosphorylation. J. Virol. 1996, 70:2420-2430.
150. Staebler A., Pierce J.H., Brazinski S., Heidaran M.A., Li W., Schlegel R., Goldstein D.J. Mutational analysis of the beta-type platelet-derived growth factor receptor defines the site of interaction with the bovine papillomavirus type 1 E5 transforming protein. J. Virol. 1995, 69:6507-6517.
151. Stoppler M.C., Straight S.W., Tsao G., Schlegel R., McCance D.J. The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA. Virology 1996, 223(1):251-254.
152. Straight S.W., Herman B., McCance D.J. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 1995, 69:3185-3192.
153. Straight S.W., Hinkle P.M., Jewers R.J., McCance D.J. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J. Virol. 1993, 67:4521-4532.
154. Suprynowicz F.A., Baege A., Sunitha I., Schlegel R. c-Src activation by the E5 oncoprotein enables transformation independently of PDGF receptor activation. Oncogene 2002, 21:1695-1706.
155. Suprynowicz F.A., Disbrow G.L., Krawczyk E., Simic V., Lantzky K., Schlegel R. HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells. Oncogene 2008, 27(8):1071-1078.
156. Suprynowicz F.A., Disbrow G.L., Simic V., Schlegel R. Are transforming properties of the bovine papillomavirus E5 protein shared by E5 from high-risk human papillomavirus type 16?. Virology 2005, 332:102-113.
157. Suprynowicz F.A., Krawczyk E., Hebert J.D., Sudarshan S.R., Simic V., Kamonjoh C.M., Schlegel R. The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification. J. Virol. 2010, 84(20):10619-10629.
158. Suprynowicz F.A., Sparkowski J., Baege A., Schlegel R. E5 oncoprotein mutants activate phosphoinositide 3'-kinase independently of platelet-derived growth factor receptor activation. J. Biol. Chem. 2000, 275:5111-5119.
159. Surti T., Klein O., Aschheim K., DiMaio D., Smith S.O. Structural models of the bovine papillomavirus E5 protein. Proteins 1998, 33(4):601-612.
160. Talbert-Slagle K., Marlatt S., Barrera F.N., Khurana E., Oates J., Gerstein M., Engelman D.M., DiMaio D. Artificial transmembrane oncoproteins smaller than the bovine papillomavirus E5 protein redefine the sequence requirements for activation of the PDGF β receptor. J. Virol. 2009, 83:9773-9785.
161. Thomsen P., van Deurs B., Norrild B., Kayser L. The HPV16 E5 oncogene inhibits endocytic trafficking. Oncogene 2000, 19:6023-6032.
162. Tomakidi P., Cheng H., Kohl A., Komposch G., Alonso A. Connexin 43 expression is downregulated in raft cultures of human keratinocytes expressing the human papillomavirus type 16 E5 protein. Cell. Tissue Res. 2000, 301:323-327.
163. Tomakidi P., Cheng H., Kohl A., Komposch G., Alonso A. Modulation of the epidermal growth factor receptor by the human papillomavirus type 16 E5 protein in raft cultures of human keratinocytes. Eur. J. Cell Biol. 2000, 79:407-412.
164. WafI/SdiI/CipI gene expression in fibroblasts and keratinocytes. J. Virol. 1996, 70:7535-7539.
165. Tsirimonaki E., Ullah R., Marchetti B., Ashrafi G.H., McGarry L., Ozanne B., Campo M.S. Similarities and differences between the E5 oncoproteins of bovine papillomaviruses type 1 and type 4: cytoskeleton, motility and invasiveness in E5-transformed bovine and mouse cells. Virus Res. 2006, 115(2):158-168.
166. Vali U., Kilk A., Ustav M. Bovine papillomavirus oncoprotein E5 affects the arachidonic acid metabolism in cells. Int. J. Biochem. Cell Biol. 2001, 33:227-235.
167. Vallee G.F., Banks L. The human papillomavirus (HPV)-6 and HPV-16 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J. Gen. Virol. 1995, 76:1239-1245.
168. van Doorslaer K. Evolution of the papillomaviridae. Virology 2013, 10.1016/j.virol.2013.05.012, this issue.
169. Venuti A., Paolini F., Nasir L., Corteggio A., Roperto S., Campo M.S., Borzacchiello G. Papillomavirus E5: the smallest oncoprotein with many functions. Mol. Cancer 2011, 10:140. 10.1186/1476-4598-10-140.
170. Venuti A., Salani D., Poggiali F., Manni V., Bagnato A. The E5 oncoprotein of human papillomavirus type 16 enhances endothelin-1-induced keratinocyte growth. Virology 1998, 248:1-5.
171. Wetherill L.F., Holmes K.K., Verow M., Muller M., Howell G., Harris M., Fishwick C., Stonehouse N., Foster R., Blair G.E., Griffin S., Macdonald A. High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors. J. Virol. 2012, 86(9):5341-5351.
172. Windisch D., Hoffmann S., Afonin S., Vollmer S., Benamira S., Langer B., Burck J., Muhle-Goll C., Ulrich A.S. Structural role of the conserved cysteines in the dimerization of the viral transmembrane oncoprotein E5. Biophys. J. 2010, 99(6):1764-1772.
173. Yang D.H., Wildeman A.G., Sharom F.J. Overexpression, purification, and structural analysis of the hydrophobic E5 protein from human papillomavirus type 16. Protein Expr. Purif. 2003, 30(1):1-10.
174. Yuan Z., Gault E.A., Campo M.S., Nasir L. Different contribution of bovine papillomavirus type 1 oncoproteins to the transformation of equine fibroblasts. J. Gen. Virol. 2011, 92(PART 4):773-783.
175. Yuan Z., Gault E.A., Campo M.S., Nasir L. p38 mitogen-activated protein kinase is crucial for bovine papillomavirus type-1 transformation of equine fibroblasts. J. Gen. Virol. 2011, 92(PART 8):1778-1786.
176. Zhang B., Li P., Wang E., Brahmi Z., Dunn K.W., Blum J.S., Roman A. The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-γ. Virology 2003, 310:100-108.
177. Zhang B., Spandau D.F., Roman A. E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis. J. Virol. 2002, 76:220-231.
178. Zhang B., Srirangam A., Potter D.A., Roman A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005.
179. Zhang Y., Lehman J.M., Petti L.M. Apoptosis of mortal human fibroblasts transformed by the bovine papillomavirus E5 oncoprotein. Mol. Cancer Res. 2002, 1:122-136.
180. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009, 384(2):260-265.